- Home
- OPY vs REPL Comparison
OPY vs REPL Comparison
Compare OPY & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPY
- REPL
- Stock Information
- Founded
- OPY 1881
- REPL 2015
- Country
- OPY United States
- REPL United States
- Employees
- OPY N/A
- REPL N/A
- Industry
- OPY Investment Bankers/Brokers/Service
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- OPY Finance
- REPL Health Care
- Exchange
- OPY Nasdaq
- REPL Nasdaq
- Market Cap
- OPY 651.2M
- REPL 1.1B
- IPO Year
- OPY N/A
- REPL 2018
- Fundamental
- Price
- OPY $62.61
- REPL $13.98
- Analyst Decision
- OPY
- REPL Strong Buy
- Analyst Count
- OPY 0
- REPL 6
- Target Price
- OPY N/A
- REPL $19.83
- AVG Volume (30 Days)
- OPY 20.3K
- REPL 624.5K
- Earning Date
- OPY 01-31-2025
- REPL 02-12-2025
- Dividend Yield
- OPY 1.14%
- REPL N/A
- EPS Growth
- OPY 145.95
- REPL N/A
- EPS
- OPY 6.37
- REPL N/A
- Revenue
- OPY $1,344,505,000.00
- REPL N/A
- Revenue This Year
- OPY N/A
- REPL N/A
- Revenue Next Year
- OPY N/A
- REPL $1,065.54
- P/E Ratio
- OPY $9.89
- REPL N/A
- Revenue Growth
- OPY 13.93
- REPL N/A
- 52 Week Low
- OPY $36.93
- REPL $4.92
- 52 Week High
- OPY $73.12
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- OPY 37.44
- REPL 55.54
- Support Level
- OPY $62.35
- REPL $13.40
- Resistance Level
- OPY $66.38
- REPL $14.59
- Average True Range (ATR)
- OPY 1.74
- REPL 0.84
- MACD
- OPY -0.60
- REPL -0.02
- Stochastic Oscillator
- OPY 4.06
- REPL 66.52
About OPY Oppenheimer Holdings Inc. (DE)
Oppenheimer Holdings Inc conducts activities in the securities industry. The company is involved in retail securities brokerage, investment banking (both corporate and public finance), institutional sales and trading, market-making, research, trust services, and investment advisory and asset management services. The company has three segments: private client, asset management, and capital markets. The Private Client segment, commissions and a proportionate amount of fee income earned on assets under management ("AUM"), net interest earnings on client margin loans and cash balances, fees from money market funds, and custodian fees. The company generates the majority of its revenue from the Americas, with the rest from Europe, the Middle East, and Asia.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.